{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:23:41Z","timestamp":1791912221795,"version":"4.3.4"},"reference-count":228,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2010,7,21]],"date-time":"2010-07-21T00:00:00Z","timestamp":1279670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit the isoenzymes COX-1 and COX-2 of cyclooxygenase (COX). Renal side effects (e.g., kidney function, fluid and urinary electrolyte excretion) vary with the extent of COX-2-COX-1 selectivity and the administered dose of these compounds. While young healthy subjects will rarely experience adverse renal effects with the use of NSAIDs, elderly patients and those with co-morbibity (e.g., congestive heart failure, liver cirrhosis or chronic kidney disease) and drug combinations (e.g., renin-angiotensin blockers, diuretics plus NSAIDs) may develop acute renal failure. This review summarizes our present knowledge how traditional NSAIDs and selective COX-2 inhibitors may affect the kidney under various experimental and clinical conditions, and how these drugs may influence renal inflammation, water transport, sodium and potassium balance and how renal dysfunction or hypertension may result.<\/jats:p>","DOI":"10.3390\/ph3072291","type":"journal-article","created":{"date-parts":[[2010,7,22]],"date-time":"2010-07-22T02:23:06Z","timestamp":1279765386000},"page":"2291-2321","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":228,"title":["Nonsteroidal Anti-Inflammatory Drugs and the Kidney"],"prefix":"10.3390","volume":"3","author":[{"given":"Walter H.","family":"H\u00f6rl","sequence":"first","affiliation":[{"name":"Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, W\u00e4hringer G\u00fcrtel 18-20, A-1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2010,7,21]]},"reference":[{"key":"ref_1","first-page":"18","article-title":"Epidemiology of NSAID induced gastrointestinal complications","volume":"56","author":"Singh","year":"1999","journal-title":"J. Rheumatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1046\/j.1365-2796.2003.01146.x","article-title":"Adverse renal effects of anti-inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors","volume":"253","author":"Gambaro","year":"2003","journal-title":"J. Intern. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1345\/aph.1D296","article-title":"Nephrotoxic potential of selective cyclooxygenase-2 inhibitors","volume":"38","author":"Sandhu","year":"2004","journal-title":"Ann. Pharmacother."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1097\/00005344-200605001-00007","article-title":"COX-2 and the Kidney","volume":"47","author":"Harris","year":"2006","journal-title":"J. Cardiovasc Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.2174\/0929867043365279","article-title":"New developments on thromboxane and prostacyclin modulators part II: prostacyclin modulators","volume":"11","author":"Hanson","year":"2004","journal-title":"Curr. Med. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"SI-53","DOI":"10.3949\/ccjm.69.Suppl_1.SI53","article-title":"Renal effects of nonselective NSAIDs and coxibs","volume":"69","author":"Weir","year":"2002","journal-title":"Cleve. Clin. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0014-5793(99)01088-1","article-title":"Immunolocalization of cyclooxygenase-2 in the macula densa of human elderly","volume":"457","author":"Nantel","year":"1999","journal-title":"FEBS Lett."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1172\/JCI8539","article-title":"The macula densa is worth its salt","volume":"104","author":"Schnermann","year":"1999","journal-title":"J. Clin. Invest."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1681\/ASN.V11122387","article-title":"Cyclooxygenase-2 in the kidney","volume":"11","author":"Harris","year":"2000","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2165\/00002018-200225030-00003","article-title":"Cyclo-oxygenase-2 inhibitors and the kidney: a case for caution","volume":"25","author":"Noroian","year":"2002","journal-title":"Drug Saf."},{"key":"ref_11","first-page":"3","article-title":"Weighing the renal effects of NSAIDs and COX-2 inhibitors","volume":"1","author":"Weir","year":"2000","journal-title":"Clin. Dilemmas"},{"key":"ref_12","first-page":"1301","article-title":"Practical considerations for the use of nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors in hypertension and kidney disease","volume":"18","author":"LeLorier","year":"2002","journal-title":"Can. J. Cardiol."},{"key":"ref_13","first-page":"F460","article-title":"Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function","volume":"272","author":"Klein","year":"1997","journal-title":"Am. J. Physiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/0002-9343(85)90223-2","article-title":"Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function","volume":"78","author":"Carmichael","year":"1985","journal-title":"Am. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1177\/009127000204200905","article-title":"Effects of celecoxib and diclofenac on blood pressure, renal function, and vasoactive prostanoids in young and elderly subjects","volume":"42","author":"Dilger","year":"2002","journal-title":"J. Clin. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S0009-9236(99)90087-5","article-title":"Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans","volume":"65","author":"Schwartz","year":"1999","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0009-9236(99)70056-1","article-title":"Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects","volume":"66","author":"Rossat","year":"1999","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_18","first-page":"265","article-title":"Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor","volume":"4","author":"Patrignani","year":"2003","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1046\/j.1365-2036.2003.01460.x","article-title":"Review article: The pharmacological properties and clinical use of valdecoxib, a new cyclo-oxygenase-2-selective inhibitor","volume":"17","author":"Alsalameh","year":"2003","journal-title":"Aliment Pharmacol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1001\/archinte.160.10.1465","article-title":"Effects of celecoxib and naproxen on renal function in the elderly","volume":"160","author":"Whelton","year":"2000","journal-title":"Arch. Intern. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-133-1-200007040-00002","article-title":"Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial","volume":"133","author":"Swan","year":"2000","journal-title":"Ann. Intern. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/00045391-200103000-00003","article-title":"Cyclooxygenase-2\u2013specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients","volume":"8","author":"Whelton","year":"2001","journal-title":"Am. J. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0002-9149(02)02661-9","article-title":"Effects of celecoxib and rofecoxib on blood pressure and edema in patients>or = 65 years of age with systemic hypertension and osteoarthritis","volume":"90","author":"Whelton","year":"2002","journal-title":"Am. J. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"65S","DOI":"10.1016\/S0002-9343(99)00369-1","article-title":"Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2-selective inhibition","volume":"107","author":"Brater","year":"1999","journal-title":"Am. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1023\/A:1007122706770","article-title":"Acute effects of the anti-inflammatory cyclooxygenase-2 selective inhibitor, flosulide, on renal plasma flow and glomerular filtration rate in rats","volume":"25","author":"Turull","year":"2001","journal-title":"Inflammation"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMra0809139","article-title":"Renal failure in cirrhosis","volume":"361","author":"Schrier","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0016-5085(99)70020-X","article-title":"Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites","volume":"116","author":"Titos","year":"1999","journal-title":"Gastroenterology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/sj.bjp.0704528","article-title":"Cyclooxygenase-1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites","volume":"135","author":"Titos","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"ref_29","first-page":"309","article-title":"Role of prostaglandins and thromboxane in the control of renal hemodynamics in experimental liver cirrhosis","volume":"113","author":"Leehey","year":"1989","journal-title":"J. Lab. Clin. Med."},{"key":"ref_30","first-page":"915","article-title":"Role of nitric oxide and prostacyclin in the control of renal perfusion in experimental cirrhosis","volume":"22","author":"Ros","year":"1995","journal-title":"Hepatology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/hep.20595","article-title":"Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites","volume":"41","author":"Kent","year":"2005","journal-title":"Hepatology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/hep.20744","article-title":"Safety of short-term administration of celecoxib in decompensated cirrhosis","volume":"42","author":"Campbell","year":"2005","journal-title":"Hepatology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/00365520310008205","article-title":"Effect of celecoxib on renal function in cirrhotic patients with ascites. A pilot study","volume":"39","author":"Guevara","year":"2004","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/hep.20763","article-title":"Safety of short-term administration of celecoxib in decompensated cirrhosis","volume":"42","year":"2005","journal-title":"Hepatology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0016-5085(79)90268-3","article-title":"Effect of indomethacin and prostaglandin A1 on renal function and plasma renin activity in alcoholic liver disease","volume":"77","author":"Boyer","year":"1979","journal-title":"Gastroenterology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1210\/jcem-48-6-895","article-title":"Prostaglandins: modulators of renal function and pressor resistance in chronic liver disease","volume":"48","author":"Zipser","year":"1979","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2362.1983.tb00100.x","article-title":"Sympathetic nervous activity, renin-angiotensin system and renal excretion of prostaglandin E2 in cirrhosis. Relationship to functional renal failure and sodium and water excretion","volume":"13","author":"Arroyo","year":"1983","journal-title":"Eur. J. Clin. Invest."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/hep.1840030108","article-title":"Effect of inhibitors of prostaglandin synthesis on induced diuresis in cirrhosis","volume":"3","author":"Mirouze","year":"1983","journal-title":"Hepatology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1159\/000183692","article-title":"Sulindac reduces the urinary excretion of prostaglandins and impairs renal function in cirrhosis with ascites","volume":"42","author":"Quintero","year":"1986","journal-title":"Nephron"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/00000441-198709000-00007","article-title":"Reversible acute decrease in renal function by NSAIDs in cirrhosis","volume":"294","author":"Brater","year":"1987","journal-title":"Am. J. Med. Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1152\/physrev.1996.76.2.425","article-title":"Paracrine regulation of the renal microcirculation","volume":"76","author":"Navar","year":"1996","journal-title":"Physiol. Rev."},{"key":"ref_42","first-page":"R263","article-title":"Juxtaglomerular cell complex in the regulation of renal salt excretion","volume":"274","author":"Schnermann","year":"1998","journal-title":"Am. J. Physiol."},{"key":"ref_43","first-page":"F605","article-title":"Cyclooxygenase-2 participates in tubular flow-dependent afferent arteriolar tone: interaction with neuronal NOS","volume":"275","author":"Ichihara","year":"1998","journal-title":"Am. J. Physiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1161\/01.HYP.29.1.297","article-title":"Cyclooxygenase-2 mediates increased renal renin content induced by low-sodium diet","volume":"29","author":"Harding","year":"1997","journal-title":"Hypertension"},{"key":"ref_45","first-page":"F825","article-title":"Nitric oxide and prostaglandins are involved in the macula densa control of the renin system","volume":"269","author":"Schricker","year":"1995","journal-title":"Am. J. Physiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1172\/JCI5505","article-title":"Angiotensin II attenuates renal cortical cyclooxygenase-2 expression","volume":"103","author":"Cheng","year":"1999","journal-title":"J. Clin. Invest."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0009-9236(01)49789-X","article-title":"Low sodium and furosemide-induced stimulation of the renin system in man is mediated by cyclooxygenase 2","volume":"70","author":"Kammerl","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"37922","DOI":"10.1074\/jbc.M006218200","article-title":"Low chloride stimulation of prostaglandin E2 release and cyclooxygenase-2 expression in a mouse macula densa cell line","volume":"275","author":"Yang","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_49","first-page":"F706","article-title":"Inhibition of macula densa-stimulated renin secretion by pharmacological blockade of cyclooxygenase-2","volume":"277","author":"Traynor","year":"1999","journal-title":"Am. J. Physiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1172\/JCI200318018","article-title":"Luminal NaCl delivery regulates basolateral PGE2 release from macula densa cells","volume":"112","author":"Komlosi","year":"2003","journal-title":"J. Clin. Invest."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/01.HYP.34.1.96","article-title":"Cyclooxygenase-2 inhibition decreases renin content and lowers blood pressure in a model of renovascular hypertension","volume":"34","author":"Wang","year":"1999","journal-title":"Hypertension"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"R1179","DOI":"10.1152\/ajpregu.00340.2002","article-title":"Cyclooxygenase-2 contributes to elevated renin in the early postnatal period in rats","volume":"284","author":"Stubbe","year":"2003","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"F449","DOI":"10.1152\/ajprenal.2001.280.3.F449","article-title":"Genetic deletion of COX-2 prevents increased renin expression in response to ACE inhibition","volume":"280","author":"Cheng","year":"2001","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1046\/j.1523-1755.2001.00072.x","article-title":"Deficiency of COX-1 causes natriuresis and enhanced sensitivity to ACE inhibition","volume":"60","author":"Athirakul","year":"2001","journal-title":"Kidney Int."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/00041552-200109000-00009","article-title":"Renal effects of cyclooxygenase-2 selective inhibitors","volume":"10","author":"Harris","year":"2001","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"F122","DOI":"10.1152\/ajprenal.2000.279.1.F122","article-title":"Nitric oxide regulates renal cortical cyclooxygenase-2 expression","volume":"279","author":"Cheng","year":"2000","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1046\/j.1365-201x.2000.00642.x","article-title":"Interactions of the renin-angiotensin system and neuronal nitric oxide synthase in regulation of cyclooxygenase-2 in the macula densa","volume":"168","author":"Harris","year":"2000","journal-title":"Acta Physiol. Scand."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1172\/JCI10318","article-title":"Role of p38 in the regulation of renal cortical cyclooxygenase-2 expression by extracellular chloride","volume":"106","author":"Cheng","year":"2000","journal-title":"J. Clin. Invest."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1172\/JCI9956","article-title":"Dehydration activates an NF-kappaB-driven, COX2-dependent survival mechanism in renal medullary interstitial cells","volume":"106","author":"Hao","year":"2000","journal-title":"J. Clin. Invest."},{"key":"ref_60","first-page":"516","article-title":"Renal complications associated with use of nonsteroidal anti-inflammatory agents","volume":"43","author":"Palmer","year":"1995","journal-title":"J. Investig. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"13S","DOI":"10.1016\/S0002-9343(99)00113-8","article-title":"Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications","volume":"106","author":"Whelton","year":"1999","journal-title":"Am. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1139\/y04-129","article-title":"Effect of nonsteroidal anti-inflammatory drugs with varying extent of COX-2-COX-1 selectivity on urinary sodium and potassium excretion in the rat","volume":"83","author":"Harirforoosh","year":"2005","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/j.1440-1681.2006.04464.x","article-title":"Extent of renal effect of cyclo-oxygenase-2-selective inhibitors is pharmacokinetic dependent","volume":"33","author":"Harirforoosh","year":"2006","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000046212","article-title":"Renal effects of COX-2-selective inhibitors","volume":"21","author":"Brater","year":"2001","journal-title":"Am. J. Nephrol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1067\/mcp.2002.126182","article-title":"Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet","volume":"72","author":"Schwartz","year":"2002","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1440-1797.2006.00562.x","article-title":"Effect of indomethacin and selective cyclooxygenase-2 inhibitors on proteinuria and renal function in patients with AA type renal amyloidosis","volume":"11","author":"Kahvecioglu","year":"2006","journal-title":"Nephrology (Carlton)"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0149-2918(04)90007-0","article-title":"Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials","volume":"26","author":"Curtis","year":"2004","journal-title":"Clin. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"R1751","DOI":"10.1152\/ajpregu.90985.2008","article-title":"Renal and cardiovascular characterization of COX-2 knockdown mice","volume":"296","author":"Seta","year":"2009","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1172\/JCI117620","article-title":"Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction","volume":"94","author":"Harris","year":"1994","journal-title":"J. Clin. Invest."},{"key":"ref_70","first-page":"F994","article-title":"Cyclooxygenase-2 in rat nephron development","volume":"273","author":"Zhang","year":"1997","journal-title":"Am. J. Physiol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1177\/019262339802600504","article-title":"Interspecies differences in renal localization of cyclooxygenase isoforms: implications in nonsteroidal antiinflammatory drug-related nephrotoxicity","volume":"26","author":"Khan","year":"1998","journal-title":"Toxicol. Pathol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/0092-8674(95)90125-6","article-title":"Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse","volume":"83","author":"Morham","year":"1995","journal-title":"Cell"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/378406a0","article-title":"Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II","volume":"378","author":"Dinchuk","year":"1995","journal-title":"Nature"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/0092-8674(95)90126-4","article-title":"Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration","volume":"83","author":"Langenbach","year":"1995","journal-title":"Cell"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0085-2538(15)46757-2","article-title":"Cyclooxygenase-2-selective inhibitors impair glomerulogenesis and renal cortical development","volume":"57","author":"Wang","year":"2000","journal-title":"Kidney Int."},{"key":"ref_76","first-page":"F926","article-title":"Macrophages, monocyte chemoattractant peptide-1, and TGF-beta 1 in experimental hydronephrosis","volume":"266","author":"Diamond","year":"1994","journal-title":"Am. J. Physiol."},{"key":"ref_77","first-page":"148","article-title":"Monocyte chemoattractant protein-1 in normal and diseased human kidneys: an immunohistochemical analysis","volume":"44","author":"Prodjosudjadi","year":"1995","journal-title":"Clin. Nephrol."},{"key":"ref_78","first-page":"536","article-title":"Glomerular expression of monocyte chemoattractant protein-1 in experimental and human glomerulonephritis","volume":"71","author":"Rovin","year":"1994","journal-title":"Lab. Invest."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/ki.1993.346","article-title":"Increased expression of monocyte chemoattractant protein-1 in anti-thymocyte antibody-induced glomerulonephritis","volume":"44","author":"Stahl","year":"1993","journal-title":"Kidney Int."},{"key":"ref_80","first-page":"282","article-title":"Gamma interferon stimulates monocyte chemotactic protein (MCP-1) in human mesangial cells","volume":"123","author":"Grandaliano","year":"1994","journal-title":"J. Lab. Clin. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.4049\/jimmunol.148.7.2148","article-title":"Cytokine-induced production of monocyte chemoattractant protein-1 by cultured human mesangial cells","volume":"148","author":"Rovin","year":"1992","journal-title":"J. Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.4049\/jimmunol.150.5.1971","article-title":"Regulation of monocyte chemoattractant protein-1 and macrophage colony-stimulating factor-1 by IFN-gamma, tumor necrosis factor-alpha, IgG aggregates, and cAMP in mouse mesangial cells","volume":"150","author":"Satriano","year":"1993","journal-title":"J. Immunol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.4049\/jimmunol.146.4.1212","article-title":"Dexamethasone inhibits the induction of monocyte chemotactic-activating factor production by IL-1 or tumor necrosis factor","volume":"146","author":"Mukaida","year":"1991","journal-title":"J. Immunol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1681\/ASN.V76897","article-title":"Prostaglandin E1 reduces the glomerular mRNA expression of monocyte-chemoattractant protein 1 in anti-thymocyte antibody-induced glomerular injury","volume":"7","author":"Jocks","year":"1996","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1046\/j.1523-1755.1999.00265.x","article-title":"Cyclooxygenase metabolites mediate glomerular monocyte chemoattractant protein-1 formation and monocyte recruitment in experimental glomerulonephritis","volume":"55","author":"Schneider","year":"1999","journal-title":"Kidney Int."},{"key":"ref_86","first-page":"F39","article-title":"Regulation of prostaglandin endoperoxide synthase gene expression in rat mesangial cells by interleukin-1 beta","volume":"266","author":"Rzymkiewicz","year":"1994","journal-title":"Am. J. Physiol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0006-2952(97)00154-8","article-title":"Expression of mitogen-inducible cyclooxygenase induced by lipopolysaccharide: mediation through both mitogen-activated protein kinase and NF-kappaB signaling pathways in macrophages","volume":"54","author":"Hwang","year":"1997","journal-title":"Biochem. Pharmacol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1681\/ASN.V93408","article-title":"Expression and localization of cyclooxygenase isoforms and cytosolic phospholipase A2 in anti-Thy-1 glomerulonephritis","volume":"9","author":"Hirose","year":"1998","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1046\/j.1523-1755.1999.00742.x","article-title":"Effect of flosulide, a selective cyclooxygenase 2 inhibitor, on passive heymann nephritis in the rat","volume":"56","author":"Blume","year":"1999","journal-title":"Kidney Int."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1681\/ASN.V971202","article-title":"Upregulation of renal and systemic cyclooxygenase-2 in patients with active lupus nephritis","volume":"9","author":"Tomasoni","year":"1998","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1365-2249.1990.tb05188.x","article-title":"Prostaglandin E1 suppresses macrophage infiltration and ameliorates injury in an experimental model of macrophage-dependent glomerulonephritis","volume":"79","author":"Cattell","year":"1990","journal-title":"Clin. Exp. Immunol."},{"key":"ref_92","first-page":"531","article-title":"Effect of prostaglandin E on immune complex nephritis in NZB\/W mice","volume":"41","author":"Kelley","year":"1979","journal-title":"Lab. Invest."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/ki.1996.302","article-title":"Prostaglandin E1 inhibits collagen expression in anti-thymocyte antibody-induced glomerulonephritis: possible role of TGF beta","volume":"50","author":"Schneider","year":"1996","journal-title":"Kidney Int."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1042\/BJ20090420","article-title":"Prostaglandin EP2 and EP4 receptors modulate expression of the chemokine CCL2 (MCP-1) in response to LPS-induced renal glomerular inflammation","volume":"422","author":"Zahner","year":"2009","journal-title":"Biochem. J."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1096\/fj.01-0390rev","article-title":"Cyclooxygenase-independent actions of cyclooxygenase inhibitors","volume":"15","author":"Tegeder","year":"2001","journal-title":"FASEB J."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1681\/ASN.V9122308","article-title":"The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin","volume":"9","author":"Perico","year":"1998","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1124\/jpet.102.043604","article-title":"Inhibition of cyclooxygenases reduces complement-induced glomerular epithelial cell injury and proteinuria in passive Heymann nephritis","volume":"305","author":"Takano","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/ki.1987.147","article-title":"Indomethacin reduces proteinuria in passive Heymann nephritis in rats","volume":"31","author":"Zoja","year":"1987","journal-title":"Kidney Int."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1159\/000181478","article-title":"Treatment of the nephrotic syndrome with indomethacin","volume":"22","author":"Donker","year":"1978","journal-title":"Nephron"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1001\/jama.1979.03290380040025","article-title":"Indomethacin and the nephrotic syndrome","volume":"241","author":"Shehadeh","year":"1979","journal-title":"JAMA"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"F1495","DOI":"10.1152\/ajprenal.00602.2007","article-title":"Suppression of cytokine responses by indomethacin in podocytes: a mechanism through induction of unfolded protein response","volume":"295","author":"Okamura","year":"2008","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1097\/01.ASN.0000031702.86799.B9","article-title":"Cyclosporine A suppresses cyclooxygenase-2 expression in the rat kidney","volume":"13","author":"Dreher","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_103","first-page":"1631","article-title":"Cyclosporine in common clinical practice: an estimation of the benefit\/risk ratio in patients with rheumatoid arthritis","volume":"21","author":"Landewe","year":"1994","journal-title":"J. Rheumatol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1172\/JCI10228","article-title":"Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes","volume":"107","author":"Komers","year":"2001","journal-title":"J. Clin. Invest."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"688","DOI":"10.2337\/db07-1230","article-title":"The effect of cyclooxygenase-2 inhibition on renal hemodynamic function in humans with type 1 diabetes","volume":"57","author":"Cherney","year":"2008","journal-title":"Diabetes"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1046\/j.1523-1755.2000.00093.x","article-title":"A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats","volume":"57","author":"Wang","year":"2000","journal-title":"Kidney Int."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1464-5491.1988.tb00961.x","article-title":"Elevated urinary prostaglandin excretion and the effect of indomethacin on renal function in incipient diabetic nephropathy","volume":"5","author":"Mathiesen","year":"1988","journal-title":"Diabet. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1681\/ASN.V591684","article-title":"Renal effects of oral prostaglandin suppl.ementation after ibuprofen in diabetic subjects: a double-blind, placebo-controlled, multicenter trial","volume":"5","author":"Bakris","year":"1995","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"F1336","DOI":"10.1152\/ajprenal.00574.2007","article-title":"Renal hemodynamic effect of cyclooxygenase 2 inhibition in young men and women with uncomplicated type 1 diabetes mellitus","volume":"294","author":"Cherney","year":"2008","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.2337\/dc09-2340","article-title":"Renal hyperfiltration is a determinant of endothelial function responses to cyclooxygenase 2 inhibition in type 1 diabetes","volume":"33","author":"Cherney","year":"2010","journal-title":"Diabetes Care"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000229304","article-title":"Chronic COX inhibition reduces diabetes-induced hyperfiltration, proteinuria, and renal pathological markers in 36-week B6-Ins2(Akita) mice","volume":"30","author":"Nasrallah","year":"2009","journal-title":"Am. J. Nephrol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1046\/j.1523-1755.2002.00520.x","article-title":"Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension","volume":"62","author":"Cheng","year":"2002","journal-title":"Kidney Int."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1161\/HYPERTENSIONAHA.109.140236","article-title":"Reactive oxygen species and cyclooxygenase 2-derived thromboxane A2 reduce angiotensin II type 2 receptor vasorelaxation in diabetic rat resistance arteries","volume":"55","author":"Retailleau","year":"2010","journal-title":"Hypertension"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1097\/01.ju.0000143882.52960.ee","article-title":"Cyclooxygenase-2 inhibitor preserves medullary aquaporin-2 expression and prevents polyuria after ureteral obstruction","volume":"172","author":"Cheng","year":"2004","journal-title":"J. Urol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"F322","DOI":"10.1152\/ajprenal.00061.2005","article-title":"COX-2 inhibition prevents downregulation of key renal water and sodium transport proteins in response to bilateral ureteral obstruction","volume":"289","author":"Jensen","year":"2005","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"F1322","DOI":"10.1152\/ajprenal.00394.2006","article-title":"COX-2 activity transiently contributes to increased water and NaCl excretion in the polyuric phase after release of ureteral obstruction","volume":"292","author":"Jensen","year":"2007","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1097\/01.ju.0000082964.24635.15","article-title":"Regional expression of cyclooxygenase isoforms in the rat kidney in complete unilateral ureteral obstruction","volume":"170","author":"Chou","year":"2003","journal-title":"J. Urol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"R1017","DOI":"10.1152\/ajpregu.00336.2009","article-title":"Urinary tract obstruction induces transient accumulation of COX-2-derived prostanoids in kidney tissue","volume":"298","author":"Jensen","year":"2010","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"11663","DOI":"10.1073\/pnas.90.24.11663","article-title":"Cellular and subcellular immunolocalization of vasopressin-regulated water channel in rat kidney","volume":"90","author":"Nielsen","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"F1051","DOI":"10.1152\/ajprenal.90202.2008","article-title":"Dehydration-induced increase in aquaporin-2 protein abundance is blocked by nonsteroidal anti-inflammatory drugs","volume":"298","author":"Baggaley","year":"2010","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_121","first-page":"F527","article-title":"Enhanced intrarenal angiotensin II generation in response to obstruction of the pig ureter","volume":"263","author":"Knudsen","year":"1992","journal-title":"Am. J. Physiol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1038\/ki.1995.408","article-title":"Sequential changes in renal expression of renin-angiotensin system genes in acute unilateral ureteral obstruction","volume":"48","author":"Pimentel","year":"1995","journal-title":"Kidney Int."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1172\/JCI109683","article-title":"Obstructive nephropathy in the rat: possible roles for the renin-angiotensin system, prostaglandins, and thromboxanes in postobstructive renal function","volume":"65","author":"Yarger","year":"1980","journal-title":"J. Clin. Invest."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"F1021","DOI":"10.1152\/ajprenal.00387.2005","article-title":"Angiotensin II mediates downregulation of aquaporin water channels and key renal sodium transporters in response to urinary tract obstruction","volume":"291","author":"Jensen","year":"2006","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"F941","DOI":"10.1152\/ajprenal.00605.2009","article-title":"Cyclooxygenase 2 inhibition exacerbates AQP2 and pAQP2 downregulation independently of V2 receptor abundance in the postobstructed kidney","volume":"298","author":"Jensen","year":"2010","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1097\/01.ASN.0000145877.28811.82","article-title":"Indomethacin enhances shuttling of aquaporin-2 despite decreased abundance in rat kidney","volume":"15","author":"Kim","year":"2004","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/archinte.1989.00390050095019","article-title":"Indomethacin in the treatment of lithium-induced nephrogenic diabetes insipidus","volume":"149","author":"Allen","year":"1989","journal-title":"Arch. Intern. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s00467-003-1195-0","article-title":"Treatment of congenital nephrogenic diabetes insipidus by hydrochlorothiazide and cyclooxygenase-2 inhibitor","volume":"18","author":"Pattaragarn","year":"2003","journal-title":"Pediatr. Nephrol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"F642","DOI":"10.1152\/ajprenal.00287.2004","article-title":"Lithium treatment inhibits renal GSK-3 activity and promotes cyclooxygenase 2-dependent polyuria","volume":"288","author":"Rao","year":"2005","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"F702","DOI":"10.1152\/ajprenal.00366.2007","article-title":"Treating lithium-induced nephrogenic diabetes insipidus with a COX-2 inhibitor improves polyuria via upregulation of AQP2 and NKCC2","volume":"294","author":"Kim","year":"2008","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0149-2918(03)90003-8","article-title":"The impact of nonsteroidal anti-inflammatory drugs on blood pressure, with an emphasis on newer agents","volume":"25","author":"Armstrong","year":"2003","journal-title":"Clin. Ther."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/nrd1225","article-title":"COX-2 and beyond: Approaches to prostaglandin inhibition in human disease","volume":"2","author":"FitzGerald","year":"2003","journal-title":"Nat. Rev. Drug. Discov."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1161\/01.HYP.0000112225.27560.24","article-title":"Role for thromboxane receptors in angiotensin-II-induced hypertension","volume":"43","author":"Francois","year":"2004","journal-title":"Hypertension"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1172\/JCI0214752","article-title":"Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II","volume":"110","author":"Qi","year":"2002","journal-title":"J. Clin. Invest."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1172\/JCI27540","article-title":"Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function","volume":"116","author":"Cheng","year":"2006","journal-title":"J. Clin. Invest."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCRESAHA.109.204529","article-title":"Cyclooxygenase-2-dependent prostacyclin formation and blood pressure homeostasis: targeted exchange of cyclooxygenase isoforms in mice","volume":"106","author":"Yu","year":"2010","journal-title":"Circ. Res."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study","volume":"284","author":"Silverstein","year":"2000","journal-title":"JAMA"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group","volume":"343","author":"Bombardier","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S0002-9149(97)00514-6","article-title":"Nonsteroidal anti-inflammatory drugs (NSAIDs) and blood pressure","volume":"80","author":"Ram","year":"1997","journal-title":"Am. J. Cardiol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"289","DOI":"10.7326\/0003-4819-121-4-199408150-00011","article-title":"Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis","volume":"121","author":"Johnson","year":"1994","journal-title":"Ann. Intern. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2165\/00002018-199717050-00001","article-title":"NSAIDs and increased blood pressure. What is the clinical significance?","volume":"17","author":"Johnson","year":"1997","journal-title":"Drug. Saf."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0272-6386(00)70266-6","article-title":"Are selective COX-2 inhibitors nephrotoxic?","volume":"35","author":"Perazella","year":"2000","journal-title":"Am. J. Kidney Dis."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00228-007-0400-7","article-title":"Clinical use and pharmacological properties of selective COX-2 inhibitors","volume":"64","author":"Shi","year":"2008","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/sj.ki.5001766","article-title":"Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen","volume":"70","author":"Whelton","year":"2006","journal-title":"Kidney Int."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1001\/archinte.165.2.161","article-title":"The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus","volume":"165","author":"Sowers","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/art.20855","article-title":"Cardiovascular death in rheumatoid arthritis: a population-based study","volume":"52","author":"Nicola","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa050405","article-title":"Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention","volume":"352","author":"Solomon","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.phrs.2009.01.011","article-title":"Nonsteroidal antiinflammatory drugs: past, present and future","volume":"59","author":"Patrono","year":"2009","journal-title":"Pharmacol. Res."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S0140-6736(08)60137-3","article-title":"COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs","volume":"371","author":"Warner","year":"2008","journal-title":"Lancet"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1124\/mol.109.057844","article-title":"Differential effects of selective cyclooxygenase-2 inhibitors on vascular smooth muscle ion channels may account for differences in cardiovascular risk profiles","volume":"76","author":"Brueggemann","year":"2009","journal-title":"Mol. Pharmacol."},{"key":"ref_151","first-page":"15","article-title":"Novel actions of nonsteroidal anti-inflammatory drugs on vascular ion channels: accounting for cardiovascular side effects and identifying new therapeutic applications","volume":"2","author":"Brueggemann","year":"2010","journal-title":"Mol. Cell Pharmacol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1124\/mol.109.059683","article-title":"An ion channel hypothesis to explain divergent cardiovascular safety of cyclooxygenase-2 inhibitors: the answer to a hotly debated puzzle?","volume":"76","author":"Shapiro","year":"2009","journal-title":"Mol. Pharmacol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1001\/jama.296.13.jrv60015","article-title":"Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials","volume":"296","author":"Zhang","year":"2006","journal-title":"JAMA"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"ii11","DOI":"10.1093\/rheumatology\/keq057","article-title":"Patient benefit-risk in arthritis\u2013a rheumatologist's perspective","volume":"49","author":"Bijlsma","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"ref_155","first-page":"193","article-title":"Renal safety of combined cyclooxygenase 2 (COX-2) inhibitor and angiotensin II receptor blocker administration in mild volume depletion","volume":"131","author":"Kistler","year":"2001","journal-title":"Swiss Med. Wkly."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"R638","DOI":"10.1152\/ajpregu.00150.2002","article-title":"Prostaglandins that increase renin production in response to ACE inhibition are not derived from cyclooxygenase-1","volume":"283","author":"Cheng","year":"2002","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1517\/14740330903311023","article-title":"Renal adverse effects of nonsteroidal anti-inflammatory drugs","volume":"8","author":"Harirforoosh","year":"2009","journal-title":"Expert. Opin. Drug Saf."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1001\/archinte.167.21.2371-b","article-title":"Arthritis is associated with cardiovascular disease in the users of analgesics and nonsteroidal anti-inflammatory drugs","volume":"167","author":"Jamali","year":"2007","journal-title":"Arch. Intern. Med."},{"key":"ref_159","unstructured":"Kaplan, N.M. Up to Date. Available online:www.uptodate.com."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/archinte.165.5.ioi50013","article-title":"Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure","volume":"165","author":"Aw","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/archinte.1993.00410040045007","article-title":"A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure","volume":"153","author":"Pope","year":"1993","journal-title":"Arch. Intern. Med."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2165\/00003495-199651020-00001","article-title":"Nonsteroidal anti-inflammatory drugs and hypertension. The risks in perspective","volume":"51","year":"1996","journal-title":"Drugs"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"628","DOI":"10.7326\/0003-4819-107-5-628","article-title":"Ibuprofen interferes with the efficacy of antihypertensive drugs. A randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen","volume":"107","author":"Radack","year":"1987","journal-title":"Ann. Intern. Med."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"M74","DOI":"10.1093\/gerona\/51A.2.M74","article-title":"The impact of ibuprofen on the efficacy of antihypertensive treatment with hydrochlorothiazide in elderly persons","volume":"51","author":"Gurwitz","year":"1996","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"184","DOI":"10.5694\/j.1326-5377.2000.tb125548.x","article-title":"Diuretics, ACE inhibitors and NSAIDs\u2013the triple whammy","volume":"172","author":"Thomas","year":"2000","journal-title":"Med. J. Aust."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1097\/00007611-199210000-00010","article-title":"Changes in residents' attitudes in response to residency program modifications: a prospective study","volume":"85","author":"Seelig","year":"1992","journal-title":"South Med. J."},{"key":"ref_167","first-page":"164","article-title":"Interaction of prostaglandins and angiotensin II in the modulation of renal function in congestive heart failure","volume":"77","author":"Packer","year":"1988","journal-title":"Circulation"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1253\/jcj.63.1002","article-title":"Syncope caused by nonsteroidal anti-inflammatory drugs and angiotensin-converting enzyme inhibitors","volume":"63","author":"Kurata","year":"1999","journal-title":"Jpn. Circ. J."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1177\/014107680109401005","article-title":"Nephrotoxicity in the elderly due to co-prescription of angiotensin converting enzyme inhibitors and nonsteroidal anti-inflammatory drugs","volume":"94","author":"Adhiyaman","year":"2001","journal-title":"J. R. Soc. Med."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.0306-5251.2004.2188.x","article-title":"Drug combinations and impaired renal function\u2013the 'triple whammy'","volume":"59","author":"Loboz","year":"2005","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0022-3565(25)32257-3","article-title":"Pharmacokinetic-dynamic analysis of the indomethacin-furosemide interaction in man","volume":"215","author":"Chennavasin","year":"1980","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1007\/s00467-006-0224-1","article-title":"Indomethacin decreases furosemide-induced natriuresis and diuresis on the neonatal kidney","volume":"21","author":"Reyes","year":"2006","journal-title":"Pediatr. Nephrol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/BF00582381","article-title":"Effect of inhibitors of prostaglandin synthesis on the furosemide action in the loop Henle of rat kidney","volume":"411","author":"Greven","year":"1988","journal-title":"Pflugers Arch."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00228-006-0190-3","article-title":"The influence of cardiovascular and antiinflammatory drugs on thiazide-induced hemodynamic and saluretic effects","volume":"62","author":"Knauf","year":"2006","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1046\/j.1523-1755.2001.00988.x","article-title":"Inhibition of COX-2 counteracts the effects of diuretics in rats","volume":"60","author":"Kammerl","year":"2001","journal-title":"Kidney Int."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1111\/j.1523-1755.2004.00627.x","article-title":"Cyclosporine A attenuates the natriuretic action of loop diuretics by inhibition of renal COX-2 expression","volume":"65","author":"Kees","year":"2004","journal-title":"Kidney Int."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.jacc.2008.08.036","article-title":"Resistant hypertension: an overview of evaluation and treatment","volume":"52","author":"Sarafidis","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/sj.bjp.0704821","article-title":"Cyclo-oxygenase-2 inhibition increases blood pressure in rats","volume":"136","author":"Endemann","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"R1767","DOI":"10.1152\/ajpregu.00786.2004","article-title":"Interactions between 11beta-hydroxysteroid dehydrogenase and COX-2 in kidney","volume":"288","author":"Yao","year":"2005","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"F294","DOI":"10.1152\/ajprenal.00347.2001","article-title":"Role of prostanoids in regulation of the renin-angiotensin-aldosterone system by salt intake","volume":"283","author":"Kammerl","year":"2002","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1172\/JCI0214752","article-title":"Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II","volume":"110","author":"Qi","year":"2002","journal-title":"J. Clin. Invest."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1161\/01.HYP.0000014323.99765.16","article-title":"Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors","volume":"39","author":"White","year":"2002","journal-title":"Hypertension"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0149-2918(03)90017-8","article-title":"The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care","volume":"25","author":"Harley","year":"2003","journal-title":"Clin. Ther."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1524-6175.2003.00514.x","article-title":"The effect of nonsteroidal anti-inflammatory drugs on blood pressure in patients treated with different antihypertensive drugs","volume":"5","author":"Morgan","year":"2003","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/archinte.1995.00430100075009","article-title":"The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil","volume":"155","author":"Houston","year":"1995","journal-title":"Arch. Intern. Med."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"289","DOI":"10.7326\/0003-4819-121-4-199408150-00011","article-title":"Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis","volume":"121","author":"Johnson","year":"1994","journal-title":"Ann. Intern. Med."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/qjmed\/90.6.411","article-title":"Increased salt retention and hypertension from non-steroidal agents in the elderly","volume":"90","author":"Mulkerrin","year":"1997","journal-title":"QJM"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"F119","DOI":"10.1152\/ajprenal.2001.280.1.F119","article-title":"Acute upregulation of COX-2 by renal artery stenosis","volume":"280","author":"Mann","year":"2001","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/01.HYP.34.1.96","article-title":"Cyclooxygenase-2 Inhibition Decreases Renin Content and Lowers Blood Pressure in a Model of Renovascular Hypertension","volume":"34","author":"Wang","year":"1999","journal-title":"Hypertension"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"F1782","DOI":"10.1152\/ajprenal.00513.2006","article-title":"COX-2 activity determines the level of renin expression but is dispensable for acute upregulation of renin expression in rat kidneys","volume":"292","author":"Matzdorf","year":"2007","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_191","first-page":"2680","article-title":"Nonsteroidal antiinflammatory drug toxicity monitoring and safety practices","volume":"30","author":"Patino","year":"2003","journal-title":"J. Rheumatol."},{"key":"ref_192","first-page":"1371","article-title":"NSAID prescribing precautions","volume":"80","author":"Risser","year":"2009","journal-title":"Am. Fam. Physician"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/oxfordjournals.aje.a010234","article-title":"Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons","volume":"151","author":"Griffin","year":"2000","journal-title":"Am. J. Epidemiol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00045391-199701000-00011","article-title":"Acute renal papillary necrosis induced by ibuprofen","volume":"4","author":"Atta","year":"1997","journal-title":"Am. J. Ther."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"394","DOI":"10.7326\/0003-4819-133-5-200009050-00024","article-title":"Acute renal failure associated with rofecoxib","volume":"133","author":"Wolf","year":"2000","journal-title":"Ann. Intern. Med."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1161\/01.HYP.34.3.503","article-title":"Inhibition of the renin-angiotensin system upregulates cyclooxygenase-2 expression in the macula densa","volume":"34","author":"Wolf","year":"1999","journal-title":"Hypertension"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10787-009-0016-x","article-title":"Ibuprofen: pharmacology, efficacy and safety","volume":"17","author":"Rainsford","year":"2009","journal-title":"Inflammopharmacology"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/archinte.168.12.1325","article-title":"Prevention, incidence, and outcomes of contrast-induced acute kidney injury","volume":"168","author":"Weisbord","year":"2008","journal-title":"Arch. Intern. Med."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.bcp.2003.09.023","article-title":"Indomethacin-induced renal damage: role of oxygen free radicals","volume":"67","author":"Basivireddy","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00204-005-0658-4","article-title":"Indomethacin induces free radical-mediated changes in renal brush border membranes","volume":"79","author":"Basivireddy","year":"2005","journal-title":"Arch. Toxicol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ki.2008.557","article-title":"COX-2 inhibition attenuates endotoxin-induced downregulation of organic anion transporters in the rat renal cortex","volume":"75","author":"Schmidt","year":"2009","journal-title":"Kidney Int."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1681\/ASN.2008101097","article-title":"Over-the-counter analgesic use","volume":"20","author":"Elseviers","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00045391-199701000-00011","article-title":"Acute renal papillary necrosis induced by ibuprofen","volume":"4","author":"Atta","year":"1997","journal-title":"Am. J. Ther."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0022-3476(80)80126-0","article-title":"Renal papillary necrosis in juvenile rheumatoid arthritis","volume":"97","author":"Wortmann","year":"1980","journal-title":"Pediatr."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S0140-6736(82)90638-9","article-title":"Indamethacin-induced renal papillary necrosis in juvenile chronic arthritis","volume":"2","author":"Mitchell","year":"1982","journal-title":"Lancet"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/bmj.285.6343.694","article-title":"Benoxaprofen and papillary necrosis","volume":"285","author":"Erwin","year":"1982","journal-title":"Br. Med. J. (Clin. Res. Ed.)"},{"key":"ref_207","first-page":"90","article-title":"Renal papillary necrosis due to naproxen","volume":"11","author":"Caruana","year":"1984","journal-title":"J. Rheumatol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1007\/s00467-003-1167-4","article-title":"Renal papillary necrosis induced by naproxen","volume":"18","author":"Kovacevic","year":"2003","journal-title":"Pediatr. Nephrol."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1159\/000185079","article-title":"Does paracetamol cause urothelial cancer or renal papillary necrosis?","volume":"49","author":"McCredie","year":"1988","journal-title":"Nephron"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1001\/archinte.1983.00350090053009","article-title":"Epidemiologic study of regular analgesic use and end-stage renal disease","volume":"143","author":"Murray","year":"1983","journal-title":"Arch. Intern. Med."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1056\/NEJM198905113201903","article-title":"Analgesic use and chronic renal disease","volume":"320","author":"Sandler","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1365-2125.1990.tb03841.x","article-title":"End-stage renal disease and non-narcotic analgesics: a case-control study","volume":"30","author":"Morlans","year":"1990","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1159\/000168002","article-title":"Regular analgesic intake and the risk of end-stage renal failure","volume":"9","author":"Pommer","year":"1989","journal-title":"Am. J. Nephrol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2105\/AJPH.80.2.153","article-title":"Occupational and other exposures associated with male end-stage renal disease: a case\/control study","volume":"80","author":"Steenland","year":"1990","journal-title":"Am. J. Public. Health"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJM199412223312502","article-title":"Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs","volume":"331","author":"Perneger","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jama.286.3.315","article-title":"Analgesic use and renal function in men","volume":"286","author":"Rexrode","year":"2001","journal-title":"JAMA"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa010323","article-title":"Acetaminophen, aspirin, and chronic renal failure","volume":"345","author":"Fored","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/archinte.164.14.1519","article-title":"Lifetime nonnarcotic analgesic use and decline in renal function in women","volume":"164","author":"Curhan","year":"2004","journal-title":"Arch. Intern. Med."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"165","DOI":"10.7326\/0003-4819-115-3-165","article-title":"Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease","volume":"115","author":"Sandler","year":"1991","journal-title":"Ann. Intern. Med."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/pds.1798","article-title":"Selective and non-selective non-steroidal anti-inflammatory drugs and the risk of acute kidney injury","volume":"18","author":"Lafrance","year":"2009","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"280.e1","DOI":"10.1016\/j.amjmed.2006.02.015","article-title":"NSAID use and progression of chronic kidney disease","volume":"120","author":"Gooch","year":"2007","journal-title":"Am. J. Med."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.semarthrit.2008.08.001","article-title":"Nonsteroidal anti-inflammatory drugs: adverse effects and their prevention","volume":"39","author":"Vonkeman","year":"2010","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_223","first-page":"81s","article-title":"Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond","volume":"11","year":"2008","journal-title":"J. Pharm. Pharmaceut. Sci."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1021\/jm050211k","article-title":"Novel nonsteroidal antiinflammatory drugs possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety: design, synthesis, biological evaluation, and nitric oxide release studies","volume":"48","author":"Rao","year":"2005","journal-title":"J. Med. Chem."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.tips.2009.01.001","article-title":"Cyclooxygenase-inhibiting nitric oxide donators for osteoarthritis","volume":"30","author":"Wallace","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1124\/pr.59.3.1","article-title":"Membrane prostaglandin E synthase-1: a novel therapeutic target","volume":"59","author":"Samuelsson","year":"2007","journal-title":"Pharmacol. Rev."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1124\/jpet.108.138776","article-title":"MF63 [2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation","volume":"326","author":"Xu","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1124\/jpet.107.134510","article-title":"MF498 [N-{[4-(5,9-Diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide], a selective E prostanoid receptor 4 antagonist, relieves joint inflammation and pain in rodent models of rheumatoid and osteoarthritis","volume":"325","author":"Clark","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/3\/7\/2291\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T22:02:58Z","timestamp":1760220178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/3\/7\/2291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,21]]},"references-count":228,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2010,7]]}},"alternative-id":["ph3072291"],"URL":"https:\/\/doi.org\/10.3390\/ph3072291","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,21]]}}}